About SeQuent Scientific Limited

SeQuent Scientific Limited is India’s leading animal health company with a global presence across over 90 countries, offering Active Pharmaceutical Ingredients (APIs), finished dosage formulations (FDF), and analytical services through 7 manufacturing facilities as part of its group operations, as stated in the Annual Report 2024–25 corporate and financial statement notes. The Company was incorporated in 1985 and presented its Fortieth Annual Report for the year ended March 31, 2025, reflecting its long-standing industry presence and evolution into a top-20 global animal health player by scale and reach per its general information and management discussion disclosures. Registered in Hyderabad, Telangana, SeQuent operates through subsidiaries including Alivira Animal Health Limited and multiple overseas entities, supporting worldwide market access and supply chains in animal health products and services, as captured in corporate information and director profiles. The Company’s activities cover development and manufacture of veterinary APIs and formulations, alongside contract and analytical offerings aligned to regulated and emerging markets demand, with a strategic focus on pipeline acceleration and operational excellence for sustained growth. Foreign investment stood at 52.61% of paid-up share capital as at March 31, 2025, underscoring global sponsorship; the Company reports no foreign collaborations, per statutory disclosures. Key milestones disclosed include consolidated revenue growth in FY 2024–25 and profitability improvement with PAT at the consolidated level, supported by operational initiatives and portfolio execution detailed in the Board’s Report.

SeQuent Scientific Limited Business Segment

• SeQuent operates in animal health across APIs, formulations (FDF), and analytical services; the Annual Report frames the business as a unified animal health vertical serving global markets through group entities and sites, without a quantified segmental revenue split disclosed in the cited sections.

• Percentage contribution to revenue by segment/vertical and by domestic vs. international was not disclosed in the accessible sections; hence, this section is skipped per instruction when not disclosed.
  

SeQuent Scientific Limited Key Management

• Rajaram Narayanan — Managing Director and Chief Executive Officer.

• Saurav Bhala — Chief Financial Officer.

• Yoshita Vora — Company Secretary.

Latest Updates on SeQuent Scientific Limited

• FY 2024–25 consolidated revenue was Rs 1,551.37 crore, up 13.26% year-on-year from Rs 1,369.73 crore, with consolidated profit after tax of Rs 32.26 crore versus a loss of Rs 29.61 crore in FY 2023–24, reflecting improved execution and cost discipline per the Board’s Report; units in “million” imply Rs 1551.37 crore and Rs 1369.73 crore, respectively, applying the instruction to treat “million” amounts as Rs crore with two decimals as presented.

• Standalone revenue was Rs 178.26 crore and PAT was Rs 15.79 crore in FY 2024–25, showing improved profitability over the prior year per the standalone statement of profit and loss.

• Strategic focus areas highlighted include pipeline acceleration in R&D, profit optimisation, cash management, and tighter working capital and cost controls to reinforce financial resilience and growth readiness, per Annexure B narrative.

• Operational sustainability initiatives included a 73.5 KW rooftop solar installation generating 45,040 KWH (July 2023–March 2024), energy-efficiency upgrades (IE4 motors, VFDs), and waste reduction/reuse actions (effluent recycling, boiler ash to bricks), aligned with compliance and resource efficiency goals in the BRSR section.

• Business continuity and onsite emergency plans were affirmed across corporate offices and major manufacturing facilities, assigning site-head responsibility during emergencies, as disclosed in risk and continuity reporting.